Defence Therapeutics Inc.
DTC
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.65% | -72.60% | -75.91% | -61.17% | -67.06% |
| Depreciation & Amortization | -42.62% | -27.88% | -22.31% | 130.41% | 405.84% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.86% | -72.51% | -76.66% | -64.27% | -63.05% |
| Operating Income | 14.86% | 72.51% | 76.66% | 64.27% | 63.05% |
| Income Before Tax | -3.76% | 69.68% | 74.08% | 73.59% | 70.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.76% | 69.68% | 74.08% | 73.38% | 70.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.76% | 69.68% | 74.08% | 73.38% | 70.20% |
| EBIT | 14.86% | 72.51% | 76.66% | 64.27% | 63.05% |
| EBITDA | 14.30% | 72.78% | 76.99% | 64.82% | 63.63% |
| EPS Basic | 12.42% | 73.74% | 76.80% | 74.81% | 71.48% |
| Normalized Basic EPS | 10.68% | 73.11% | 76.26% | 74.08% | 71.72% |
| EPS Diluted | 12.42% | 73.74% | 76.80% | 74.81% | 71.48% |
| Normalized Diluted EPS | 10.68% | 73.11% | 76.26% | 74.08% | 71.72% |
| Average Basic Shares Outstanding | 17.68% | 13.96% | 9.86% | 6.05% | 6.96% |
| Average Diluted Shares Outstanding | 17.68% | 13.96% | 9.86% | 6.05% | 6.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |